CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) rose 7.8% during trading on Friday . The company traded as high as $0.15 and last traded at $0.14. Approximately 1,923,801 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 2,548,531 shares. The stock had previously closed at $0.13.
CytoDyn Trading Up 7.8 %
The company has a 50 day simple moving average of $0.13 and a two-hundred day simple moving average of $0.14. The firm has a market capitalization of $168.27 million, a P/E ratio of -6.90 and a beta of 0.14.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last released its earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 EPS for the quarter.
About CytoDyn
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Recommended Stories
- Five stocks we like better than CytoDyn
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Where Do I Find 52-Week Highs and Lows?
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
